Hudson Bay Capital Management
APVO icon

Hudson Bay Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Hudson Bay Capital Management’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70
Closed -$168K – 918
2024
Q3 		$168K Buy
70
+32
+84% +$147K ﹤0.01% 753
2024
Q2 		$153K Buy
+38
New +$567K ﹤0.01% 668

Other funds holding APVO

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFFP
Center for Financial Planning Southfied, Michigan $1.07B AUM 18.98% 1-Year Est. Return

Hudson Bay Capital Management's APVO Position: Q4 2024 in Review

Hudson Bay Capital Management sold out of Aptevo Therapeutics (APVO) in Q4 2024, closing a stake of 70 shares — an estimated $168K sold.

Hudson Bay Capital Management first reported a position in APVO in Q2 2024 and held it in 2 quarters. The position peaked at $168K in Q3 2024. 7 funds tracked by Wall St. Rank hold APVO as of Q4 2024.

  • Hudson Bay Capital Management reported no remaining Aptevo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 70 Aptevo Therapeutics shares in Q4 2024, an estimated $168K.
  • Hudson Bay Capital Management first reported a position in Aptevo Therapeutics in Q2 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Aptevo Therapeutics position peaked at $168K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2024.

Based on Hudson Bay Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.